@bronxb_13 Bronx Kid
Bronx Kid posts on X about $capr, $qure, sap, $repl the most. They currently have [--] followers and [---] posts still getting attention that total [---] engagements in the last [--] hours.
Engagements: [---] #
- [--] Week [-----] +975%
- [--] Month [-----] +21%
- [--] Months [---------] -93%
- [--] Year [----------] +1,492%
Mentions: [--] #
- [--] Months [---] +506%
- [--] Year [---] +1,471%
Followers: [--] #
- [--] Week [--] -1.20%
- [--] Month [--] +5.10%
- [--] Months [--] +1,267%
CreatorRank: [---------] #
Social Influence
Social category influence finance 13% technology brands 11% stocks 5% social networks 3% cryptocurrencies 3% countries 1% exchanges 1%
Social topic influence $capr 42%, $qure 8%, sap 7%, $repl 4%, money 3%, $srpt 3%, has been 3%, end of 2%, rfk 2%, fired 2%
Top accounts mentioned or mentioned by @rnaianalyst @fidelisaurelius @martinshkreli @drsprs @augurbio @markland55 @biotenic @enigmaticstocks @seedy19tron @jonnyfunguy @truetrueike @plainyogurt21 @ttramyloid @adamfeuerstein @zm2514 @jacqueskahn @pickingmyown @mickeychiku @sanctuarybio @applehelix
Top assets mentioned uniQure N.V. (QURE) Sarepta Therapeutics, Inc. (SRPT) OREx (OREX) Dyne Therapeutics, Inc. (DYN) Opendoor Technologies Inc Common Stock (OPEN) The Official [--] Coin (67) Alphabet Inc Class A (GOOGL)
Top Social Posts
Top posts by engagements in the last [--] hours
"RT @matthewherper: @anish_koka Hmm. You used to not like it when officials over-ruled staff. https://x.com/anish_koka/status/1925382095200800874s=20 https://x.com/anish_koka/status/1925382095200800874s=20"
X Link 2026-02-11T22:56Z [--] followers, [--] engagements
"RT @PearlF: The FDA's head of CBER has reportedly been accused of se*xual harassment of FDA employees & retaliation according to WSJ stor"
X Link 2026-02-12T13:55Z [--] followers, [--] engagements
"$CAPR has approx $330 million in cash on hand ($98.6 million end of Q3 + atm sales at $28 per share $75 million + full offering at $175 million). It is currently trading at approx [---] times cash value with a MC of $1.17 billion. Should be trading at a minimum [--] x cash. (1 of 2)"
X Link 2026-01-29T13:26Z [--] followers, [---] engagements
"@FidelisAurelius Crazy. HOPE-3 is arguably the strongest dataset ever produced in dmd especially for nonambulant. I understand that this FDA is whacko but they arent stupid. Amazing buying opportunity even at these levels IMO $CAPR"
X Link 2026-01-29T14:05Z [--] followers, [---] engagements
"When your ex stalks your instagram$CAPR Trying to get burned twice"
X Link 2026-02-09T14:47Z [--] followers, [--] engagements
"@mickeychiku dont need a formal FDA meeting to submit topline data; can go in thru written correspondence/email or gateway sub. CSR request after topline review is routine for a BLA resubnot proof of a meeting. The short thesis here has gone down substantially. Clutching at straws"
X Link 2026-02-11T22:04Z [--] followers, [--] engagements
"@Sanctuary_Bio Youre lumping $CAPR in but its an entirely different case than the others you listed (REPL QURE etc.). This FDA/Prasad is on record saying exactly whats needed (P3 results). They are no longer relying on regulatory flexibility as much as the other examples. Others too early"
X Link 2026-02-11T23:53Z [--] followers, [---] engagements
"@Sanctuary_Bio He was right to give it imo. Their p2 had small n and didnt use a prespecified SAP by VP. They met with Prasads CBER prior to p3 unblinding and have type a minutes that the p3 is sufficient for approval and got alignment on a pre-specified SAP. Adcoms dont happen anymore"
X Link 2026-02-12T00:17Z [--] followers, [---] engagements
"@AppleHelix He wont be fired for this. This is literally the reason he has this job in the first place. RFK hired him to go after vaccines / MRNA. He has to do this or hed be fired and replaced with someone who will"
X Link 2026-02-12T13:20Z [--] followers, [---] engagements
"@TrueTrueIke RGNX is def more evidence of bear case for how they will deal with QURE. As I think we spoke about I dont see p3 being avoidable for them unfortunately. MRNA I read a bit differently. I view this as Prasads mandate for being in his position. RFK JR very against mRNA vaccines"
X Link 2026-02-12T19:10Z [--] followers, [---] engagements
"@RNAiAnalyst Right bullish $QURE but youre bearish $CAPR. Makes a lot of sense 🤷🏼♂"
X Link 2026-02-12T19:36Z [--] followers, [---] engagements
"RT @bijans: Prasad is facing several personnel complaints filed against him including some that involve sexual harassment retaliation ag"
X Link 2026-02-12T13:30Z [--] followers, [--] engagements
"Can someone please start a polymarket or Kalshi bet on Vinay Prasad out at FDA by end of [----] This way he might actually get fired so some other Trump official can cash in on it"
X Link 2026-02-12T13:38Z [--] followers, [---] engagements
"RT @LauraLoomer: I see Vinay Prasad is back in the news again. I always warned that Vinay Prasad @VPrasadMDMPH was a terrible hire at the"
X Link 2026-02-13T18:13Z [--] followers, [---] engagements
"RT @AppleHelix: The most eye-rolling part of this tweet is that VP is going to teach us clinical trial design and regulations 1) VP ne"
X Link 2026-02-14T00:49Z [--] followers, [--] engagements
"RT @SashaGusevPosts: Sorry folks FDA is no longer considering treatments for conditions that aren't clearly visible on an unscaled plot. Y"
X Link 2026-02-14T03:16Z [--] followers, [--] engagements
"@TCellEngager @plainyogurt21 @Biotenic If it were 0% chance the market would be pricing the stock around cash ($2 SP)"
X Link 2025-09-20T19:04Z [--] followers, [---] engagements
"@TCellEngager @plainyogurt21 @Biotenic This is why they want to get on same page about SAP endpoints etc. with FDA before unblinding P3. They got screwed over when Mark and Verdun left because this was the pathway they were told to follow after the Soslow study came out"
X Link 2025-09-20T22:08Z [--] followers, [---] engagements
"@MartinShkreli Why no RCT and small N. Why do you say that for this drug and not for others with similar circumstances Also not clear VP is aligned with them on regulatory pathway based off his prior stance on similar drugs (for example $CAPR)"
X Link 2025-09-24T13:31Z [--] followers, [----] engagements
"@Biotenic Lets see what happens with their SAP submission. If FDA allows non parametric analysis for PUL [---] (and possibly for LVEF as well) I do not see it as a clear straight shot fail unless I am missing something"
X Link 2025-09-25T15:19Z [--] followers, [---] engagements
"@boopdotpng @dashwend @MaryBschanck Yes on that point I agree with you. The company has insight into the cardiac data prior to unblinding thru MRIs and know how good the cardiac data is hence the request to switch the primary to LVEF"
X Link 2025-09-26T23:09Z [--] followers, [--] engagements
"@drsprs How has $CAPR management been arrogant exactly"
X Link 2025-10-06T17:09Z [--] followers, [---] engagements
"@drsprs Got it - so what is the relation to $CAPR You think they will fail P3 If so - Why"
X Link 2025-10-06T17:12Z [--] followers, [---] engagements
"@drsprs They didnt fudge any data. The critique was they unblinded it early used a non parametric SAP and the cardiac data wasnt pre-specified. They just did all of that now in the type a meeting for the p3. They unblinded early bc they ran out of money and used non parametric bc"
X Link 2025-10-06T17:59Z [--] followers, [---] engagements
"@AscendingBio @drsprs I think this is more of a case of following the pack. A lot of shkreli fanatics on here blindly following any of his short/long calls without original thinking/any true dd"
X Link 2025-10-07T12:05Z [--] followers, [--] engagements
"@iotaresearch @ENIGMATICSTOCKS @Biotenic @MartinShkreli Really His short call on $OPEN didnt exactly go well. And his timing on $CAPR short wasnt exactly on the money either. I seem to recall a company called $OREX too that you fail to mention lol"
X Link 2025-09-26T20:23Z [--] followers, [---] engagements
"@plainyogurt21 @anthonystaj @drsprs Huh They didnt want to submit any further data until they had it in writing from the FDA in official minutes that H3 was sufficient because they were already screwed over. They got the FDA to put in writing that LVEF is a key secondary and that they will be flexible"
X Link 2025-10-19T12:16Z [--] followers, [--] engagements
"@WexCapital @rezfszubagoly Kind of like you and $ATYR. Aside from the woman part. Or maybe not "
X Link 2025-10-26T18:40Z [--] followers, [---] engagements
"@Buffalo51766917 Is this and posting about bees the best you got lol The p = .014 result was from the prespecified ANCOVA model and represents the correct statistical test for the primary endpoint. the p = [----] table simply shows unadjusted means. Two different ways of analyzing the same data"
X Link 2025-10-27T19:39Z [--] followers, [---] engagements
"@seedy19tron @Ernthestocker Curious what @A_May_MD thinks of this ticker. Hes been silent on it. General bio twitter consensus seems to be short based off copying Martin Shkreli. Havent seen any real convincing DD strongly justifying a short here"
X Link 2025-10-30T15:15Z [--] followers, [---] engagements
"@Dremontjones @bio_clouseau This did not age well. As I mentioned this FDA is a clown show. Unfortunate for Huntington disease sufferers just as it is unfortunate for DMD patients $CAPR $QURE"
X Link 2025-11-03T12:55Z [--] followers, [---] engagements
"@MattyKirsh Yes $CAPR had same thing happen to them"
X Link 2025-11-03T13:10Z [--] followers, [----] engagements
"Anyone know why $PGEN got approval with no RCT and a small P1/2 Curious why. Maybe check their management team and see if theres any connections b/w them and Prasad. I can only see one connection which tends to be a theme in this FDA"
X Link 2025-11-03T20:13Z [--] followers, [---] engagements
"@LauraLoomer Vinay prasad and this fda playing favorites. Rules for thee but not for me (or my friends/fellow Indians). Meanwhile American upstarts getting slapped with CRLs and setbacks $capr $repl and European companies with breakthroughs getting roadblocks $qure"
X Link 2025-11-03T20:19Z [--] followers, [---] engagements
"@MartinShkreli Do you still like $QURE too Both $QURE and $SRPT easily 100x from here Should change your handle to bag boy 😆"
X Link 2025-11-04T13:16Z [--] followers, [---] engagements
"@andrewpaleogos @TTRAmyloid Same story with $CAPR. The earlier trials were done based off feedback and input from the FDA. This basically signals to any biotech company out there that your P1/2 can potentially be rendered meaningless by future FDA administrations. Why would anyone invest in a biotech"
X Link 2025-11-04T18:08Z [--] followers, [---] engagements
"@adamfeuerstein $PGEN is the outlier. Why did that get approval Thats what you should be investigating"
X Link 2025-11-05T12:59Z [--] followers, [---] engagements
"Since Anthonystaj blocked me because he doesnt want any critiques of his FUD posts on $CAPR. every HOPE-2 pt was already on standard cardiac meds (ACEi -blockers steroids). Deramiocels signal came on top of those therapies not bc of them. Heres the baseline table"
X Link 2025-11-06T13:34Z [--] followers, [----] engagements
"@TrackAIPAC @MrMikeBlake @MrMikeBlake is a grifter who will go wherever the political winds fill his clipped wings. The guy is a loser. Ritchie Torres has done a fantastic job for the Bronx and his constituents"
X Link 2025-11-07T13:03Z [--] followers, [---] engagements
"@HHSGov @POTUS @SecKennedy You guys are owned by Big Pharma. The agenda isnt lining up with what you guys campaigned on. Why do you keep hampering American drug companies like $REPL $CAPR and innovators like $QURE but award big pharma with CNPV vouchers Wasnt the goal to help the small companies Clowns"
X Link 2025-11-07T13:20Z [--] followers, [---] engagements
"$CAPR has a sub $300mm MC. The average daily volume is about 1.3mm shares. There are 46mm shares outstanding. You think the company could sell 8-16mm shares ATM since Sept [--] without the price completely tanking @medtechmustache"
X Link 2025-11-08T13:30Z [--] followers, [----] engagements
"previous investors in at $17 level after BLA. those investors were confident in the drug at a $17/share level the stock at $6 seems like a great value proposition. This equates to buyers believing that the likelihood of a successful phase [--] is high and want to get in cheap"
X Link 2025-11-08T13:35Z [--] followers, [---] engagements
"@ayden_parga Also that much atm selling would need to be disclosed immediately its over 15% of the MC. IMO more likely if they are atm selling they have sold between $ 5-15mm dollars worth of shares because that is below the threshold of what they would need to disclose"
X Link 2025-11-08T14:52Z [--] followers, [--] engagements
"@idalopirdine @medtechmustache This was the price when they filed the shelf ($6.19) Price is around $6 now. This doesnt qualify as tanking when its a small cap biotech. The stock has been trading between $6-7 since the end of August"
X Link 2025-11-08T21:05Z [--] followers, [---] engagements
"@augurbio @ENIGMATICSTOCKS MOA works and has been validated. They also passed CMC already so FDA agrees . Cohort A of P3 was ready for top line in [----] but made no sense to unblind with a pending BLA / pdufa based off P2. cohort B only just finished. https://www.mdpi.com/2227-9059/13/11/2652 https://www.mdpi.com/2227-9059/13/11/2652"
X Link 2025-11-11T13:12Z [--] followers, [---] engagements
"@augurbio @ENIGMATICSTOCKS Allstar was in adults with ischemic cardiomyopathy after MI a completely different much broader pop/indication delivery route and endpoint. In DMD (rare pediatric disease) the efficacy bar and regulatory flexibility are very different. Comparing apples to oranges imo"
X Link 2025-11-11T14:46Z [--] followers, [--] engagements
"@seedy19tron Extremely bullish for $CAPR $REPL as well if true"
X Link 2025-11-11T17:24Z [--] followers, [----] engagements
"@augurbio ALLSTAR was not enrolled with any DMD patients and had a different trial design / delivery method / dosing More of an experimental trial to figure out what they were working with"
X Link 2025-11-12T00:56Z [--] followers, [--] engagements
"@Jonny_fun_guy @seedy19tron @idalopirdine Yeah seedy and snaking are the same person got the above identical comments from them and then snakings was deleted a second later lol. Guess thats the account seedy uses to pump/dump other names"
X Link 2025-11-12T19:07Z [--] followers, [---] engagements
"@Jonjon9Teen79 @docrodwong $QURE $CAPR $REPL"
X Link 2025-11-21T20:52Z [--] followers, [---] engagements
"@ZM2514 @adamfeuerstein Why u so obsessed w me zohran"
X Link 2025-11-21T22:51Z [--] followers, [---] engagements
"@HeikwanTrades U r missing the point. Has nothing to do with the companies mentioned in the letter. Why would anyone invest in ANY early stage biotech if you cant trust the guidance the FDA is giving out This flip flopping has driven investors out of the sector and killed seed funding"
X Link 2025-11-22T02:58Z [--] followers, [----] engagements
"@HeikwanTrades Have you spoken to any pre-seed/early stage biotech company personnel Very little investing in early stage rare disease at the moment from who I speak to"
X Link 2025-11-22T03:13Z [--] followers, [---] engagements
"@MartinShkreli @ENIGMATICSTOCKS @MktMachiavelli @anthonystaj Your boy Anthony that wrote your short thesis for you blocks anyone that criticizes it on X"
X Link 2025-11-26T18:37Z [--] followers, [---] engagements
"@jlucer53 @RNAiAnalyst HOPE-2 showed in vivo benefit & HOPE-3 passed its futility analysis. All H3 patients remained on drug for OLE. 4x year infusions and travel for DMD patients isnt easy if the drug does nothing"
X Link 2025-12-02T13:05Z [--] followers, [--] engagements
"@MartinShkreli Yooo $OREX come pick up your boy hes wildin again"
X Link 2025-12-03T12:46Z [--] followers, [---] engagements
"@avidresearch The data is even better after [--] months. Look at OLE data. Every kid in H3 stayed on"
X Link 2025-12-03T14:00Z [--] followers, [--] engagements
"@ZM2514 @markland_55 @augurbio Ok but you do follow what a convicted felon says blindly bc hes autistic"
X Link 2025-12-03T19:33Z [--] followers, [--] engagements
"$capr for the morons saying oh its only a 3% improvement in PUL. This is in a disease where PUL decreases 2.8-3.7 % ever year A PUL improvement is a massive difference for this population and those numbers continue year after year as seen in the 4-year OLE data"
X Link 2025-12-03T19:49Z [--] followers, [---] engagements
"@augurbio @ZM2514 @markland_55 Augur respectfully ZM has been trolling mine and marklands comments for months now. You have been respectful and I have no qualms with you. ZM is unnecessarily disrespectful"
X Link 2025-12-03T21:17Z [--] followers, [--] engagements
"@jacqueskahn They had the tables today on their slides. The prior thesis was delayed data=fail. But the company was so delayed because they needed the FDA to confirm they were in agreement on the SAP before unblinding would begin. After already getting burned they werent touching the p3 b4"
X Link 2025-12-03T22:16Z [--] followers, [--] engagements
"@RNAiAnalyst I dont think they will be fired anymore after seeing the latest CDER appointment"
X Link 2025-12-04T12:57Z [--] followers, [---] engagements
"@pinker_ste94119 Well done response The 220m recently raised also validates your analysis. Its time"
X Link 2025-12-05T12:08Z [--] followers, [---] engagements
"Exactly right. All we heard about was cope-3 capr=🧢 for almost a full year and now the shorts are smoking the most amount of copium and doing mental gymnastics to discredit the incredible hope [--] results. Move on or go long $CAPR $CAPR @Elijahjstacy I enjoy doing the work because haters gonna hate and we are all in this fight together %change vs absolute value in calculating PUL is the heated topic Dear FDA stats team and haters We hit on both Hope [--] webcast covers this point at the 1:04-1:11 mark $CAPR @Elijahjstacy I enjoy doing the work because haters gonna hate and we are all in this"
X Link 2025-12-07T14:24Z [--] followers, [----] engagements
"@RNAiAnalyst Ahhh now I understand why youre so critical of $capr results. Youre long $dyn. You do realize the two arent mutually exclusive The two therapies could complement each other and Exosomes could be used as the delivery system for PMOs to fix the safety / liver tox issues"
X Link 2025-12-08T12:53Z [--] followers, [---] engagements
"@markland_55 @RNAiAnalyst $SRPT whole business was based on AA too early those days are completely over and $DYN doesnt offer anything novel just a slightly improved drug. Run a RCT and come back in a few years"
X Link 2025-12-08T14:18Z [--] followers, [---] engagements
"$CAPR bulllllllish @Oppenheimer new PT and guidance"
X Link 2025-12-08T15:26Z [--] followers, [----] engagements
"@jacqueskahn lol they didnt delay it [--] months. Like I said study English so you can understand the earnings/investor calls. Or download the transcripts and put them into Google Translate into whatever language is your native tongue"
X Link 2025-12-09T01:27Z [--] followers, [--] engagements
"@jacqueskahn Were* I see your bio says New York but youre actually tweeting from Paraguay. if you did five minutes of research you would know that hope [--] cohort b final patient was dosed in June [----]. The company received their crl in July. Had type a meeting with fda in August minutes sept"
X Link 2025-12-09T01:51Z [--] followers, [--] engagements
"@FidelisAurelius @Jonny_fun_guy @PickingMyOwn Agreed. $CAPR complementary (especially for older boys). This would be final nail in coffin for $SRPT on the other hand"
X Link 2025-12-11T01:30Z [--] followers, [---] engagements
"$RZLT the bioX echo chamber takes another L. This is the drawback of over confidence and not being willing to listen to outside voices"
X Link 2025-12-11T13:01Z [--] followers, [---] engagements
"Interesting. This was up on Sidley Austin website and now deleted $CAPR looks like the raise closed and the book runners bought the extra 15% as well https://www.sidley.com/en/newslanding/newsannouncements/2025/12/sidley-represents-capricor-therapeutics-in-us-172-million-common-stock-offering https://www.sidley.com/en/newslanding/newsannouncements/2025/12/sidley-represents-capricor-therapeutics-in-us-172-million-common-stock-offering"
X Link 2025-12-11T15:48Z [--] followers, [----] engagements
"$CAPR Hope [--] detailed top line results from Marban Lab recent presentation. #gamesetmatch"
X Link 2025-12-15T13:03Z [--] followers, [---] engagements
"@RNAiAnalyst Yes and you left out the only one to ever hit stat sig on a P3 $CAPR"
X Link 2025-12-16T21:29Z [--] followers, [---] engagements
"@AaronRosenblum5 @biotech_hunter @TTRAmyloid Lets see what bio funds bought in come February (13F filings). From my understanding many of the top bio long funds participated. What do you know that they dont You think all the KOLs supporting its approval are lying too If so this is a grand conspiracy. Call Candace"
X Link 2025-12-22T18:22Z [--] followers, [---] engagements
"@AaronRosenblum5 @biotech_hunter @TTRAmyloid The prior crl was over the issue of using a parametric versus non parametric SAP. You should listen to the PPMD webinar they just did where they run thru hope [--] data"
X Link 2025-12-23T00:36Z [--] followers, [--] engagements
"@seedy19tron Biggest miss of the year $CAPR"
X Link 2025-12-23T15:05Z [--] followers, [---] engagements
"@Nationofhorror lol what In a closed public offering the shares have been placed with investors. Underwriters dont own the deal they distribute it. This is capital markets [---]. Maybe dont comment on things u know nothing about"
X Link 2025-12-24T00:31Z [--] followers, [--] engagements
"@Jonny_fun_guy @bull_manifestor @FidelisAurelius @PickingMyOwn Agreed with everything here except [--]. I like the name a lot the more I research but Im concerned about further dilution. Last raise was at .90 back in December [----] (currently half price) but I expect more dilution to come. They most likely do a raise when they list on nasdaq"
X Link 2025-12-24T03:12Z [--] followers, [--] engagements
"@FidelisAurelius @markland_55 @marwinho1985 I dont disagree with you it should get AA but look what happened to $QURE. This FDA doesnt care. Their P2 data was stellar as well"
X Link 2025-12-25T16:25Z [--] followers, [---] engagements
"@FidelisAurelius @markland_55 @marwinho1985 Point being you should price in a p3 to your assumptions. Not saying drug doesnt work. Just saying that this FDA has a much higher evidentiary standard than it should despite efficacy. Can shit on $CAPR p2 as well but $QURE was clean and only treatment option available and alas"
X Link 2025-12-25T16:31Z [--] followers, [---] engagements
"@MadaamCurie1911 Claiming FDA ignored a prespecified SAP while simultaneously evaluating the endpoint is contradictory. SAP finalization pre-unblinding is standard ICH E9 practice thats not the same as post hoc changes. Theres no such thing as an ignored SAP. No comments=acceptance"
X Link 2025-12-29T03:24Z [--] followers, [--] engagements
"@Drchik23 $capr"
X Link 2025-12-31T13:57Z [--] followers, [---] engagements
"@PaixTrader @Soeren_Berlin @somnambulist_68 Regarding $capr its the only dmd drug to ever achieve stat sig in a p3. More warranted for ambulant and non ambulant to be on it than any drug srpt makes. OLE shows better cardiac improvement if treated earlier and longer. Also great safety data"
X Link 2025-12-31T14:03Z [--] followers, [---] engagements
"$VNDA quick approval immediately after resubmission bodes extremely well for $CAPR bla resubmission. Could easily see this getting approved by February/March"
X Link 2025-12-31T14:18Z [--] followers, [---] engagements
"@PaixTrader @Soeren_Berlin @somnambulist_68 Cant say I agree with that. What about CAPR p3 isnt clean The label will most likely cover all DMD patients above [--] yrs old ambulant and non ambulant imo"
X Link 2025-12-31T16:11Z [--] followers, [--] engagements
"@Nationofhorror This is so cringe. I can understand the mental gymnastics it takes to say they will get a CRL but RTF is just complete and utter nonsense"
X Link 2026-01-08T03:15Z [--] followers, [--] engagements
"Linda speaking with BiotechTV 1/13 $CAPR"
X Link 2026-01-11T13:49Z [--] followers, [---] engagements
"@bradloncar Arent you speaking to $CAPR too"
X Link 2026-01-13T13:04Z [--] followers, [---] engagements
"@BullLogic Yes total nonsense. All the fud was they would require another trial. All they requested was the full CSR. This is getting approved and price is totally mismatched"
X Link 2026-01-20T16:01Z [--] followers, [--] engagements
"@Jonny_fun_guy @PickingMyOwn I like $msclf as well but to say they will eat $capr lunch is funny. They havent even started a p2 and need to raise money. Capr will hopefully have several years of commercialization and beckers as well by the time msclf even starts a p3 trial. Both could be complementary"
X Link 2025-12-10T18:43Z [--] followers, [---] engagements
"@TrueTrueIke Yeah $DYNE will need to run a p3 too although data looks promising. For msclf would need to show a massive benefit to justify AA from just a p2. Most likely would still need a large RCT p3 with endpoints that are better established for dmd (PUL LVEF etc.)"
X Link 2025-12-11T21:05Z [--] followers, [---] engagements
"@justkissmyRezpe Call Marty he can fill you in on $CAPR"
X Link 2026-01-17T15:07Z [--] followers, [---] engagements
"@Maximus_Holla You still in $CAPR"
X Link 2026-01-23T16:51Z [--] followers, [---] engagements
"@adamfeuerstein lol. This guy Common Sense is a clown. Was on the short $CAPR bandwagon with Martin Shkreli and now he is acting like a DMD patient advocate when hes really just an SRPT bag holder. Cut ur losses @commonsenseplay"
X Link 2026-01-24T00:08Z [--] followers, [---] engagements
"@DoodadDoctor I think it will be mixed results. $CAPR actually works and has great safety"
X Link 2026-01-24T12:53Z [--] followers, [---] engagements
"BANG. Kevin Tang of Tang Capital Management acquires 6.6% stake in $CAPR https://d1io3yog0oux5.cloudfront.net/capricor/sec/0001214659-26-000831/0001214659-26-000831.pdf https://d1io3yog0oux5.cloudfront.net/capricor/sec/0001214659-26-000831/0001214659-26-000831.pdf"
X Link 2026-01-26T21:34Z [--] followers, [----] engagements
"Wonder what the $CAPR beard think now Youve got Kevin Tang a real hitter who got Tidmarsh fired from CDER back in November taking an $85mm chunk of the offering. Hes comfy with the regulatory risk clearly despite an active lawsuit against FDA via Aurinia. Quick approval inc"
X Link 2026-01-26T22:22Z [--] followers, [---] engagements
"@Taintslapp12283 $CAPR. Cheap at this price and will have big funds disclosed as buying in come February. Will rip into bla resub in February"
X Link 2026-01-27T18:04Z [--] followers, [---] engagements
Limited data mode. Full metrics available with subscription: lunarcrush.com/pricing